Test Spares Extended Endocrine Therapy In Low-Risk ER+ Breast Cancer
CHICAGO—A gene test that predicts for relapse in women with estrogen receptor positive early breast cancer can identify patients with low-risk disease who could safely avoid extending their endocrine therapy beyond the standard five years, according to study findings reported …